A retrospective view of hospital pharmacy in the UK over the last 20 years Authors: Philip Wiffen, Nicola Stoner Published: 2024 ABSTRACT In this article, we describe how the landscape of hospital pharmacy has changed over the last 20 years. As well as commenting on the impact of COVID-19 on services, we describe five major advancements namely: clinical pharmacy services, the development of multi-professional teams, policy changes, attitudes to using and producing evidence, advances in technology and workforce development. Finally, there is brief comment around the future challenges for hospital pharmacy in the UK Introduction We present personal views of the developments in hospital pharmacy practice over approximately the last 20 years written from the perspectives of an editor for a European hospital pharmacy journal (PW) and a practising specialist consultant pharmacist in cancer and advanced therapy medicinal products (ATMPs) (NS). As we will show, the landscape has changed considerably, much of it for the better, though challenges around the funding of developments remains problematic. The legacy of the COVID-19 pandemic continues to impact the service. The impact was seen in terms of an increased demand on services and in sourcing medications to treat COVID-19 patients in the face of shortages. The use of PPE and rigorous infection control measures added to the challenge; such additional requirements had an effect on the mental health of staff, increasing stress levels and the need for senior managers to provide appropriate support. Hospital pharmacy had to rapidly implement new ways of working to ensure patient and staff safety; some examples of service changes have been published.1,2 (Fig. 1).Fig. 1Timeline of key events in NHS Hospital Pharmacy since the year 2004.Fig 1 Timeline of key events in NHS Hospital Pharmacy since the year 2004. Key advancements Clinical pharmacy services Clinical pharmacy services have been developing over the last 40 years or so, but this has accelerated in the last 20 years. Initially the concept of ward pharmacy developed with the role of pharmacists being little more than checking a patient’s medicine chart at the end of a bed for inaccuracies, such as wrong doses or duplicate therapies. Few pharmacists engaged with the patient other than to say what they were doing! Today a significant proportion of clinical pharmacists are physically based on a ward, day-case unit or outpatient area, engaging with clinicians and patients as a key part of their role. Engagement with clinic patients has also become part of the clinical pharmacist’s role, often taking on patient reviews and medication prescribing, or presenting clinicians with a summary of medication issues prior to the clinician/patient consultation. The development of clinical pharmacy roles has been supported with competencies in advanced and consultant frameworks, enabling the workforce to develop in clinical roles to consultant level. Consultant pharmacists have a strategic leadership role, work across organisational boundaries, and deliver direct patient care. They play a vital role in improving patient care and outcomes, advancing the pharmacy profession, and influencing healthcare policy and practice. Consultant pharmacists are role models within the pharmacy profession, and mentor, support and develop current and future pharmacy professionals to ensure that their knowledge and skills meet the needs of the NHS. The title consultant pharmacist is a protected title for those pharmacists who have been credentialled as such and have been appointed to an approved consultant post. Development of multi-professional teams The clinical pharmacy developments naturally led to the inclusion of pharmacists into multi-professional teams. This started to be evident >20 years ago, particularly in complex specialties such as infectious diseases (including HAV/AIDS), renal disease and transplantation, oncology and haematology. Pharmacists are now actively involved in the decisions of care relating to medicines. The Department of Health identified the key role of pharmacists in antimicrobial stewardship including developing guidelines, ensuring appropriate use of antimicrobials and reducing the risk of antimicrobial resistance. Specific funding was provided to create new pharmacist posts and guidance was updated in 2023.3 Policy changes NHS policies have influenced the changes to the role of the clinical pharmacist. Some of these policies include the NHS plan (2000),4 A Vision for Pharmacy in the New NHS (2003), Guidance for the Development of Consultant Pharmacist Posts (2005), the NHS 5 year forward view (2014),5 Operational productivity and performance in English NHS acute hospitals: Unwarranted variations (2016),6 Pharmacists as independent prescribers (2016), the NHS long term plan (2019), the NHS People plan (2020) and the updated guidance for the development of consultant pharmacist posts (2020). In addition, there has been guidance on medicines optimisation from both the Royal Pharmaceutical Society and the National Institute for Health and Care Excellence (NICE).7,8,9 Attitudes to using and producing evidence The evidence-based medicine (EBM) movement started >30 years ago but uptake was slow in pharmacy departments, possibly due to attitudes in medicine information departments. With the establishment of the Cochrane Collaboration in 1993, it became harder to ignore this development, which was also often resisted by senior medical clinicians. Twenty years ago, pre-registration pharmacists would undertake a project which rarely if ever was published, so it has been heartening to see a strong desire to conduct and publish research among hospital pharmacists to the point where journals have to reject a good proportion of submissions due to pressures on space. Medicines information services may not have kept pace with the developments in EBM; however, they do have a role in practice of consolidating available evidence for busy clinicians. With the development of the four pillars in advanced and consultant pharmacy practice, research and hence the production of evidence is now an integral part of a clinical pharmacist’s role. The NHS is supporting these developments via a variety of initiatives, such as the NIHR Pharmacy Incubator.10 Advances in technology Advances in electronic prescribing systems, electronic transfer of clinical pharmacy orders from ward to department, robot technologies for dispensing and assembling complex medications such as TPN and systemic anticancer treatment (SACT) are also key in the changing roles within pharmacy. Targeted treatments, personalised medicine, genomics and advanced therapy medicinal products (ATMPs) eg gene therapy, cellular therapy and tissue engineered treatments are also changing the landscape. Workforce development The pharmacist workforce is developing their competencies aligned with the clinical pharmacy frameworks from registration to consultant level. The undergraduate pharmacist degree is becoming an integrated degree with clinical practice included in the training with placements, and pharmacists graduating as prescribers in 2026. Continual professional development (CPD) for pharmacy staff is evolving in the digital age, with a variety of models of learning. There is an increasing role for pharmacy technicians to backfill the roles originally filled by pharmacists, so that all professions are working at the top of their licence. Challenges There are still considerable restraints on resources limiting what could be achieved for patient benefit. In addition, shortages of suitable personal and the increasing need for CPD cause strains in the system. We are seeing increasing interest in the use of artificial intelligence and machine learning, evidenced by submissions to pharmacy journals, which may well transform pharmacy practice – though such developments need to be handled carefully. Conclusion In conclusion, pharmacy practice has developed considerably over the last 20 years, with changes in the medicines available, patient and staffing skill mix needs, education and training, and new technologies. The future looks bright as long as sufficient resources are made available. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors CRediT authorship contribution statement Philip Wiffen: Writing – review & editing, Writing – original draft, Conceptualization. Nicola Stoner: Writing – review & editing, Writing – original draft, Conceptualization. Declaration of competing interest Both authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.